{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:34:46Z","timestamp":1791308086762,"version":"4.3.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,7,4]],"date-time":"2005-07-04T00:00:00Z","timestamp":1120435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This case\u2013control study investigated the interactions between genetic and environmental factors and inhibitor development in 108 children with haemophilia A exclusively treated with recombinant factor VIII (FVIII). Sixty patients with inhibitors were compared with 48 inhibitor\u2010free controls. Family history of inhibitors and null mutations in the<jats:italic>FVIII<\/jats:italic>gene were more prevalent in cases than in controls (20% vs. 2%,<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7001 and 83% vs. 64%,<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b704, respectively). On the other hand, there was no difference between cases and controls for such putative risk factors of inhibitor development as amniocentesis\/villocentesis, premature\/caesarean birth, breast\u2010feeding, treatment during infections\/vaccinations, surgical procedures and central nervous system bleeding. A trend was found for an increased risk of inhibitor development in children first treated at a young age (&lt;11\u2003months); however, this was not confirmed after adjusting for genetic factors. The implementation of prophylaxis was evaluated as a putative risk factor in a subgroup of 25 cases: seven who started prophylaxis prior to inhibitor development and 18 potentially eligible for prophylaxis because they were inhibitor\u2010free up to the age of 35\u2003months (i.e. the upper limit of the age range at prophylaxis onset in cases and the median age at prophylaxis onset in controls). Patients who started prophylaxis had a lower inhibitor risk than those treated on demand (adjusted odds ratio 0\u00b72, 95% confidence interval 0\u00b706\u20130\u00b79). The protective effect on inhibitor development shown by prophylaxis may represent an additional advantage prompting its use in haemophilic children.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05605.x","type":"journal-article","created":{"date-parts":[[2005,7,21]],"date-time":"2005-07-21T22:22:00Z","timestamp":1121984520000},"page":"422-427","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":167,"title":["Environmental risk factors for inhibitor development in children with haemophilia A: a case\u2013control study"],"prefix":"10.1111","volume":"130","author":[{"given":"Elena","family":"Santagostino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angiola","family":"Rocino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Mazzucconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,7,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91593-B"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00510.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613376"},{"key":"e_1_2_6_5_1","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group","volume":"83","author":"Bray G.L.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1055\/s-0037-1615871","article-title":"The role of genetics in inhibitor formation","volume":"82","author":"Cox\u2010Gill J.","year":"1999","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1600-0609.1979.tb02856.x","article-title":"Development of factor VIII antibody in haemophilic monozygotic twins","volume":"23","author":"European Study Group of Factor VIII Antibody","year":"1979","journal-title":"Scandinavian Journal of Haematology"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62704-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0038-1655944","article-title":"HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party","volume":"77","author":"Hay C.R.","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.1.216"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00655.x"},{"key":"e_1_2_6_12_1","first-page":"4994","article-title":"A Mr 46,000 human milk fat globule protein that is highly expressed in human breast tumors contains factor VIII\u2010like domains","volume":"51","author":"Larocca D.","year":"1991","journal-title":"Cancer Research"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02828.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302183280701"},{"key":"e_1_2_6_15_1","unstructured":"National Hemophilia Foundation(2001)MASAC recommendation concerning prophylaxis (prophylactic administration of clotting factor concentrate to prevent bleeding) no. 117 available at:http:\/\/www.hemophilia.org\/research\/masac\/masac117.htm."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655945"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2003.11.016"},{"issue":"3","key":"e_1_2_6_18_1","first-page":"5","article-title":"Can rFVIIa be used to postpone the use of FVIII in hemophiliac infants","volume":"10","author":"Rivard G.E.","year":"2004","journal-title":"Haemophilia"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00361.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649954"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00230.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00840.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1653759"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00451.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05605.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05605.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:05:59Z","timestamp":1706400359000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05605.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,4]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05605.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05605.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,4]]},"assertion":[{"value":"2005-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}